NCT00237588View on ClinicalTrials.gov

Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

July 31, 2005

Conditions
Hypertension
Interventions
DRUG

Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg

Trial Locations (1)

0407

Cardiovascular and Renal Research Center/ Department of Cardiology, Ullevaal University Hospital, Oslo

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Ullevaal University Hospital

OTHER

NCT00237588 - Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL) | Biotech Hunter | Biotech Hunter